^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

    Excerpt:
    ...ALK rearrangement report including details of method and cutoff used for ALK testing...
    Trial ID:
    SPECIALK
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

    Excerpt:
    ...- Patients with tumors that harbor either EGFR sensitizing mutations or ALK rearrangement....
    Trial ID:
    NCT02277457
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

    Excerpt:
    ...- Patients must have an ALK rearrangement as defined via the MATCH Master Protocol...
    Trial ID:
    NCT04439266
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

    Excerpt:
    ...- ALK rearrangement detection method is NGS and Ventana...
    Trial ID:
    NCT03647111
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

    Excerpt:
    ...- Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement...
    Trial ID:
    NCT02679170
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

    Excerpt:
    ...Documented evidence of an ALK rearrangement (by FISH, IHC, or NGS), ROS1 rearrangement (by FISH or NGS), or MET oncogene as defined by MET exon 14 skipping (NGS), MET Y1003X mutation or MET gene fusion (NGS) in NSCLC tumor specimen by a CLIA-approved laboratory....
    Trial ID:
    NCT03088930
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Descriptive Observational Study ALK-2016-CPHG

    Excerpt:
    ...- Patient ALK gene rearrangement or ROS1 gene rearrangement...
    Trial ID:
    NCT03718117
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    JTO Clin Res Rep
    Title:

    Efficacy and Tolerability of ALK/MET Combinations in Patients with ALK-Rearranged Lung Cancer with Acquired MET Amplification: A Retrospective Analysis

    Published date:
    05/31/2023
    Excerpt:
    We assembled a cohort of patients with ALK+ lung cancer and acquired MET amplification (identified by tissue or plasma) who received regimens targeting both ALK and MET....Partial responses were observed in 5 (42%) of 12 patients, including patients who received crizotinib (n=1 of 2), lorlatinib + crizotinib (n=3 of 6), and alectinib + capmatinib (n=1 of 3).
    DOI:
    https://doi.org/10.1016/j.jtocrr.2023.100534